Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-reviewed claim about increased suicidal thoughts/behaviors in patients age ≤24, close monitoring, and that AUVELITY is not approved for pediatric patients is directly supported by FDA label sections 5.1 and 8.4, with no contradictions or omitted safety-critical elements identified.
Category Scores
Accurate Statements
Suicidal thoughts and behaviors: increased risk in pediatric and young adult patients in short-term studies.
Supported by Section 5.1 (pooled analyses; increased incidence in antidepressant-treated patients age 24 years and younger) and related pediatric discussion in Section 8.4.
Closely monitor.
Supported by Section 5.1 (monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts/behaviors, especially during initial months and dose changes).
AUVELITY is not approved for pediatric patients.
Supported by Section 5.1 Table 1 footnote: “AUVELITY is not approved for use in pediatric patients.”
Unsupported Statements
Contradictions
Important Omissions
The AI-reviewed claim does not explicitly mention caregiver/family counseling language, which is included in Section 5.1 and Section 17.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements reflect FDA-labeled boxed warning/warning content and the pediatric non-approval information, without introducing contradictory or unsafe claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing explicit mention of caregiver/family counseling (present in Section 5.1 and patient counseling Section 17).
Suggested Improvement
Add that patients/caregivers should be advised to monitor for emergent suicidal ideation/behavior and alert the healthcare provider, consistent with Section 5.1 and Section 17.